"Kisspeptin for women" is searched mostly for two reasons: fertility and sexual desire. Both have real trials behind them — more than most research peptides — but the trials are small, mostly from one research group, mostly use a different form of the peptide from the one sold online, and none tested kisspeptin as an ongoing treatment for the outcomes people search for. This page lays out each setting, what was measured and in how many women, and what remains untested.
Reported adverse effects are on our kisspeptin side effects page, figures quoted for it on our kisspeptin dosage page, and its comparison with hCG as a fertility trigger in our hCG vs kisspeptin page. Nothing here is a recommendation; fertility and sexual-health decisions belong with a clinician.
What kisspeptin does in the female hormone axis
Kisspeptin is a hormone made in the hypothalamus. It switches on the GnRH neurons that set the rhythm of LH and FSH release from the pituitary, and those two hormones drive follicle growth, ovulation and the sex-hormone cycle. People born with mutations that block kisspeptin signalling do not go through puberty and are infertile, which is why researchers began testing it as a reproductive drug. A plain explainer of the molecule is on Peptide Lexicon's kisspeptin entry.
Status: no kisspeptin product is approved anywhere. Every result below comes from research trials.
Which kisspeptin: 54 or 10
Two forms appear in the literature. Kisspeptin-54 is the full-length form that circulates in blood and lasts longer after injection; almost all the women's trials below used it. Kisspeptin-10 is the 10-amino-acid active fragment; it acts more briefly and has been studied mainly in men and in diagnostic hormone tests. Products sold online as "kisspeptin" are usually kisspeptin-10. A result from a kisspeptin-54 trial is not evidence about kisspeptin-10.
The trials, by setting
| Setting | Study | Women | Design | What was measured | Result |
|---|---|---|---|---|---|
| IVF egg maturation | Jayasena/Abbara, J Clin Invest 2014 | 53 | Single injection, four doses, no control arm | Egg maturation, pregnancy | Eggs matured at every dose; 92% reached transfer; pregnancy 40% biochemical, 23% clinical |
| IVF, high OHSS risk | Abbara, J Clin Endocrinol Metab 2015 | 60 | Phase 2, randomised between doses, open-label, no hCG arm | Egg yield, OHSS, pregnancy | Maturation in 95%; no moderate, severe or critical OHSS; live birth 45% per transfer |
| Hypothalamic amenorrhoea | Jayasena, J Clin Endocrinol Metab 2009 | 10 | Randomised, double-blind, twice-daily injection vs saline, 2 weeks | LH, FSH, ovarian ultrasound | LH +24.0 IU/L on day 1 → +2.5 on day 14; no ovarian change |
| Hypothalamic amenorrhoea | Jayasena, J Clin Endocrinol Metab 2014 | 5 | Single-blind continuous IV infusion at five doses vs vehicle | LH pulses | LH pulses per 8 h: 5.0 vs 1.6; effect temporary |
| Low sexual desire (HSDD) | Thurston, JAMA Netw Open 2022 | 32 completed (40 randomised) | Double-masked, placebo-controlled crossover; one 75-minute IV infusion | Brain activity on fMRI watching erotic videos and faces | Changed activity in sexual and attraction regions; no adverse effects reported |
Sources: PMID 25036713, 26192876, 19820030, 24517142, 36287566, all read 14 October 2026.
Fertility: the strongest record, with its limits
The IVF work is the most developed part of the record. In standard IVF, a final injection — usually hCG — matures the eggs before collection, and hCG carries a risk of ovarian hyperstimulation syndrome (OHSS), which can be serious. Kisspeptin produces a shorter, more natural LH surge, which is why it was tested in women at high risk of OHSS.
In the 2015 trial of 60 such women, eggs matured in 95% and no one developed moderate, severe or critical OHSS. Across 51 embryo transfers, 45% resulted in a live birth; the 9.6 nmol/kg group had the highest rates. A 2018 laboratory follow-up of 48 IVF patients (PMID 29206944) found that cells collected after a kisspeptin trigger expressed ovarian steroid genes more strongly than after hCG or a GnRH agonist, without changing OHSS markers.
What the record does not yet show: these trials were small, open-label, and had no randomised hCG or GnRH-agonist arm, so they show that kisspeptin works as a trigger, not that it outperforms the established ones. Our hCG vs kisspeptin page sets out the comparison as far as it goes.
Missing periods: a short-lived effect
Hypothalamic amenorrhoea — periods stopping because of low weight, stress or heavy exercise — is caused by weak GnRH pulsing, so kisspeptin was a logical candidate. A single injection did raise LH and FSH strongly. But in the 2009 trial, twice-daily injections lost most of their effect: the LH rise fell from 24.0 IU/L on day one to 2.5 IU/L on day 14, and the ovaries showed no change on ultrasound. The body desensitised. The 2014 infusion study found a dose range that raised LH pulses about threefold — temporarily, in five women.
A registered phase 2 trial (NCT07224438) giving subcutaneous kisspeptin-10 (listed as "kisspeptin 112-121") to 20 women with hypothalamic amenorrhoea was recruiting in October 2026. Until it reports, there is no trial showing that kisspeptin restores periods.
Sexual desire: a brain-scan finding, not a treatment result
The 2022 JAMA Network Open trial is the one most often cited for kisspeptin and libido. It enrolled premenopausal women with hypoactive sexual desire disorder and gave each a 75-minute infusion of kisspeptin and of placebo on separate days, while scanning their brains as they watched erotic videos and looked at faces. Kisspeptin changed activity in several regions linked to sexual and attraction processing, and those changes correlated with the women's baseline distress and sexual aversion scores.
What it measured was brain activity during a single infusion in a scanner. It did not measure desire, arousal, sexual frequency or satisfaction in daily life, and it did not test repeated doses. The authors wrote that the findings "lay the foundations" for clinical applications. By comparison, the approved desire drug for premenopausal women, bremelanotide, was tested in 1,267 women over 24 weeks on a desire score — see our peptides before and after page for what that trial found.
What has not been tested in women
- Weight, body composition or metabolism as outcomes of kisspeptin treatment: no trial.
- Menopause symptoms: a PubMed search on 14 October 2026 found no treatment trial of kisspeptin for hot flushes. (A related drug class — NK3 receptor blockers such as fezolinetant — acts on neighbouring neurons and is approved for hot flushes; it is not kisspeptin.)
- Polycystic ovary syndrome: a 2019 pilot cohort of anovulatory women with PCOS found kisspeptin-54 could stimulate hormone release and ovulation "albeit with incomplete efficacy" (PMID 31820802); there is no controlled treatment trial.
- Repeated use over weeks or months for any outcome: the one repeated-dose study in women showed loss of response within two weeks.
- Kisspeptin-10 in women for fertility or desire: the women's outcome trials used kisspeptin-54.
- Breastfeeding: no study of kisspeptin as a drug in nursing women; the lactation literature on it is physiology, as our peptides and breastfeeding page shows.
For the male side of the record — testosterone and LH — see our kisspeptin vs enclomiphene comparison.